Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY.
Urology. 2022 Jul;165:59-66. doi: 10.1016/j.urology.2022.01.037. Epub 2022 Feb 6.
To analyze the utilization and safety of same-day (SDD) vs standard-length discharge (SLD) for transurethral resection (TURP), holmium laser enucleation (HoLEP), and GreenLight photovaporization (GL-PVP) of the prostate.
Using the 2015-2019 ACS-NSQIP files, the annual proportion of TURP, HoLEP, and GL-PVP performed with SDD (length of stay [LOS] = 0 days) was calculated. Patients were stratified by LOS into SDD and SLD (TURP: LOS = 1-3 days, HoLEP and GL-PVP: LOS = 1-2 days); those with longer LOS were excluded. Patients were matched 1:1 by age, body mass index, American Society of Anesthesiologists score, and modified Charlson Comorbidity Index score. We compared 30-day unplanned readmissions, reoperations, and Clavien-Dindo (CD) complications between SLD and SDD, and evaluated predictors of adverse outcomes using logistic regression.
Most GL-PVP patients underwent SDD, compared to a minority of TURP and HoLEP patients. SDD utilization increased, remained stable, and decreased over time for HoLEP, TURP, and GL-PVP, respectively. For 46,898 included cases (31,872 TURP, 2,901 HoLEP, 12,125 GL-PVP), rates of reoperation, CD I/II, or CD IV complications were comparable before and after matching. Compared to SLD, 30-day unplanned readmission rates for matched SDD patients were lower following TURP (3.48% vs 4.25%, P = .013) and HoLEP (1.93% vs 4.43%, P = .003). On multivariate regression, SLD correlated with unplanned readmission after TURP and HoLEP for both unmatched and matched cohorts.
For appropriately selected patients, SDD after TURP, HoLEP, and GL-PVP did not confer increased risk of 30-day complications, suggesting patient selection for SDD is being done with appropriate safety nationally.
分析经尿道前列腺切除术(TURP)、钬激光前列腺剜除术(HoLEP)和绿激光前列腺汽化术(GL-PVP)中当天出院(SDD)与标准长度出院(SLD)的使用情况和安全性。
利用 2015 年至 2019 年美国外科医师学会国家外科质量改进计划(ACS-NSQIP)文件,计算 TURP、HoLEP 和 GL-PVP 中 SDD(住院时间 [LOS] = 0 天)的年度比例。根据 LOS 将患者分为 SDD 和 SLD(TURP:LOS = 1-3 天,HoLEP 和 GL-PVP:LOS = 1-2 天);排除 LOS 较长的患者。按照年龄、体重指数、美国麻醉医师协会评分和改良 Charlson 合并症指数评分,对患者进行 1:1 匹配。比较 SLD 和 SDD 患者 30 天内无计划再入院、再手术和 Clavien-Dindo(CD)并发症,并使用逻辑回归评估不良结局的预测因素。
与 TURP 和 HoLEP 患者相比,大多数 GL-PVP 患者接受了 SDD。SDD 的使用率分别呈增加、稳定和减少的趋势,分别对应 HoLEP、TURP 和 GL-PVP。在纳入的 46898 例病例中(31872 例 TURP、2901 例 HoLEP、12125 例 GL-PVP),匹配前后再手术、CD I/II 或 CD IV 并发症的发生率相似。与 SLD 相比,匹配后的 SDD 患者 TURP(3.48% vs. 4.25%,P =.013)和 HoLEP(1.93% vs. 4.43%,P =.003)术后 30 天内无计划再入院率较低。多变量回归分析显示,无论是否匹配,SLD 均与 TURP 和 HoLEP 术后无计划再入院相关。
对于选择合适的患者,TURP、HoLEP 和 GL-PVP 后的 SDD 并未增加 30 天并发症的风险,这表明全国范围内对 SDD 的患者选择是安全的。